カテゴリ： GlobalData, アイルランド, 企業調査

Endo International Plc (ENDP)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Endo International Plc (ENDP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012263
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：163
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies including Endo Pharmaceuticals, Paladin Labs, Par Pharmaceutical, Litha and SOMAR. It sells generic products principally in the US across multiple therapeutic categories, comprising urology, pain management, central nervous system (CNS) disorders, immunosuppression, cancer, cardiovascular diseases and women’s health markets, among others. The company’s branded pharmaceuticals target urology, orthopedics/pediatric endocrinology and pain management markets. Endo also provides over-the-counter (OTC) products across key market segments comprising dermatology and anti-infectives. The company sells its products through independent wholesale distributors, as well as to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

Endo International Plc (ENDP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Endo International Plc, Medical Devices Deals, 2011 to YTD 2017 14
Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Endo International Plc, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Endo International Acquires Portfolio of Branded and Generic Products 20
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 21
Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 22
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 23
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 24
Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 26
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 27
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 29
Private Equity 30
Endo International Sells Grupo Farmaceutico Somar to Advent International 30
Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For US$130 Million 31
TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For US$1.9 Billion 32
Partnerships 34
IntelGenx Enters into Co-Development Agreement with Endo Ventures 34
ARIAD Pharma Enters into Distribution Agreement with Paladin 35
Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 36
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 37
Auxilium Pharma And Swedish Orphan Biovitrum Enter Into Co-Development Agreement For Xiapex 38
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 39
GVK Biosciences Enters Into Research Agreement With Endo Pharma 40
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 41
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 42
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 43
Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 44
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 45
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma 46
Paladin Labs Enters Into Distribution Agreement With Common Sense 47
Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 48
Syngene International Expands Co-Development Agreement With Endo Pharma 49
Endo Pharma Enters Into Research Collaboration With Orion 50
Licensing Agreements 51
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 51
Endo International Amends Licensing Agreement with BioSpecifics Technologies 52
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 53
Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 54
Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 56
Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 57
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 59
Endo Pharma Amends Licensing Agreement with Grunenthal 60
Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 61
Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 62
QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 63
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 65
Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 66
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 67
Paladin Labs Enters into Licensing Agreement With Immuron For Travelan 69
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor 70
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 71
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 72
MediGene Enters Into Licensing Agreement With Triton Pharma For Veregen 73
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX 74
Equity Offering 76
Endo International Raises USD2.3 Billion in Public Offering of Shares 76
Paladin Labs Completes Private Placement For US$40 Million 78
Debt Offering 80
Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 80
Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 81
Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 82
Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 83
Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 84
Endo Health Solutions Completes Private Placement Of Notes Due 2022 For US$700 Million 85
Auxilium Pharma Completes Public Offering Of Notes Due 2018 For US$350 Million 86
Par Pharma Completes Private Placement Of Notes Due 2020 For US$490 Million 87
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2019 For US$500 Million 88
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$400 Million 89
Asset Transactions 90
Rising Pharma to Acquire Three ANDAs from Endo International 90
Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 91
Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 92
Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 93
Trendlines Acquires Intellectual Property from Endo 94
AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 95
Acquisition 96
Acino Pharma Acquires Litha Healthcare from Endo International 96
Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 98
Par Pharma Acquires Innoteq for USD27 Million 100
Endo International Acquires Auxilium Pharma for USD2.6 Billion 101
Par Pharma Reportedly Acquires Ethics Bio Lab 103
Endo International Completes Acquisition of Dava Pharma for USD600 Million 104
Endo International Completes Acquisition of Grupo Farmaceutico Somar 105
Endo Health Solutions Completes Acquisition Of Paladin Labs For US$1.6 Billion 106
Par Pharma Acquires JHP Group for USD488 Million 109
Endo Health Solutions Completes Acquisition Of Boca Pharmacal For US$225 Million 110
Paladin Labs Acquires Triton Pharma 112
Paladin Labs Completes Acquisition Of Allon Therapeutics 113
Auxilium Pharma Acquires Actient From GTRC 114
Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 116
Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 117
Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For US$60.7 Million 118
Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For US$24.9 Million 120
Par Pharma Acquires Anchen Pharma For US$410 Million 121
Paladin Labs Completes Acquisition Of Labopharm 123
Endo Pharma Acquires American Medical Systems 125
Endo Pharma To Acquire A Pharma Company 127
Endo International Plc – Key Competitors 128
Endo International Plc – Key Employees 129
Endo International Plc – Locations And Subsidiaries 131
Head Office 131
Other Locations & Subsidiaries 131
Recent Developments 133
Strategy And Business Planning 133
Jul 21, 2017: Endo to Restructure Manufacturing Network 133
Financial Announcements 134
Nov 09, 2017: Endo Reports Third-Quarter 2017 Financial Results 134
Oct 30, 2017: Endo Announces Certain Preliminary Financial Results for Third-Quarter 2017 and Affirms Selected 2017 Financial Guidance 136
Aug 08, 2017: Endo Reports Second-Quarter 2017 Financial Results 137
May 09, 2017: Endo Reports First-Quarter 2017 Financial Results 139
Feb 28, 2017: Endo Reports Fourth-Quarter And Full-Year 2016 Financial Results 142
Nov 08, 2016: Endo Reports Third Quarter 2016 Financial Results 145
Aug 08, 2016: Endo Reports Second Quarter 2016 Financial Results 147
May 05, 2016: Endo Reports First Quarter 2016 Financial Results 149
Feb 29, 2016: Endo Reports Fourth Quarter And Full Year 2015 Financial Results 151
Corporate Communications 153
Nov 08, 2017: Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram 153
Dec 20, 2016: Endo Announces Appointment of Blaise Coleman as Chief Financial Officer 154
Nov 07, 2016: Endo Strengthens Leadership Team with Appointment of Two Key Executives 155
Oct 20, 2016: Endo Announces Departure of Chief Financial Officer 156
Sep 23, 2016: Endo Names Paul Campanelli President and Chief Executive Officer 157
Aug 08, 2016: Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals 158
May 05, 2016: Endo Announces Appointment of Douglas S. Ingram and Todd B. Sisitsky to its Board of Directors 159
May 05, 2016: Endo Announces Change to Senior Management Team 160
Legal and Regulatory 161
Jun 07, 2017: Endo Announces Entry of Significant Case Management Order in Mesh Multidistrict Litigation 161
Other Significant Developments 162
Jan 26, 2017: Endo Announces Actions to Drive Greater Efficiency and Business Alignment 162
Appendix 163
Methodology 163
About GlobalData 163
Contact Us 163
Disclaimer 163

List of Tables
Endo International Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Endo International Plc, Deals By Therapy Area, 2011 to YTD 2017 12
Endo International Plc, Medical Devices Deals, 2011 to YTD 2017 14
Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Endo International Acquires Portfolio of Branded and Generic Products 20
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 21
Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 22
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 23
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 24
Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 26
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 27
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 29
Endo International Sells Grupo Farmaceutico Somar to Advent International 30
Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For US$130 Million 31
TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For US$1.9 Billion 32
IntelGenx Enters into Co-Development Agreement with Endo Ventures 34
ARIAD Pharma Enters into Distribution Agreement with Paladin 35
Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 36
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 37
Auxilium Pharma And Swedish Orphan Biovitrum Enter Into Co-Development Agreement For Xiapex 38
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 39
GVK Biosciences Enters Into Research Agreement With Endo Pharma 40
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 41
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 42
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 43
Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 44
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 45
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma 46
Paladin Labs Enters Into Distribution Agreement With Common Sense 47
Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 48
Syngene International Expands Co-Development Agreement With Endo Pharma 49
Endo Pharma Enters Into Research Collaboration With Orion 50
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 51
Endo International Amends Licensing Agreement with BioSpecifics Technologies 52
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 53
Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 54
Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 56
Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 57
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 59
Endo Pharma Amends Licensing Agreement with Grunenthal 60
Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 61
Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 62
QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 63
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 65
Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 66
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 67
Paladin Labs Enters into Licensing Agreement With Immuron For Travelan 69
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor 70
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 71
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 72
MediGene Enters Into Licensing Agreement With Triton Pharma For Veregen 73
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX 74
Endo International Raises USD2.3 Billion in Public Offering of Shares 76
Paladin Labs Completes Private Placement For US$40 Million 78
Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 80
Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 81
Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 82
Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 83
Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 84
Endo Health Solutions Completes Private Placement Of Notes Due 2022 For US$700 Million 85
Auxilium Pharma Completes Public Offering Of Notes Due 2018 For US$350 Million 86
Par Pharma Completes Private Placement Of Notes Due 2020 For US$490 Million 87
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2019 For US$500 Million 88
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$400 Million 89
Rising Pharma to Acquire Three ANDAs from Endo International 90
Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 91
Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 92
Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 93
Trendlines Acquires Intellectual Property from Endo 94
AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 95
Acino Pharma Acquires Litha Healthcare from Endo International 96
Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 98
Par Pharma Acquires Innoteq for USD27 Million 100
Endo International Acquires Auxilium Pharma for USD2.6 Billion 101
Par Pharma Reportedly Acquires Ethics Bio Lab 103
Endo International Completes Acquisition of Dava Pharma for USD600 Million 104
Endo International Completes Acquisition of Grupo Farmaceutico Somar 105
Endo Health Solutions Completes Acquisition Of Paladin Labs For US$1.6 Billion 106
Par Pharma Acquires JHP Group for USD488 Million 109
Endo Health Solutions Completes Acquisition Of Boca Pharmacal For US$225 Million 110
Paladin Labs Acquires Triton Pharma 112
Paladin Labs Completes Acquisition Of Allon Therapeutics 113
Auxilium Pharma Acquires Actient From GTRC 114
Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 116
Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 117
Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For US$60.7 Million 118
Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For US$24.9 Million 120
Par Pharma Acquires Anchen Pharma For US$410 Million 121
Paladin Labs Completes Acquisition Of Labopharm 123
Endo Pharma Acquires American Medical Systems 125
Endo Pharma To Acquire A Pharma Company 127
Endo International Plc, Key Competitors 128
Endo International Plc, Key Employees 129
Endo International Plc, Other Locations 131
Endo International Plc, Subsidiaries 131

★海外企業調査レポート[Endo International Plc (ENDP)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Lupin Ltd (LUPIN)：企業の財務・戦略的SWOT分析
    Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Beam Suntory Inc.：企業の戦略・SWOT・財務分析
    Beam Suntory Inc. - Strategy, SWOT and Corporate Finance Report Summary Beam Suntory Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • SPI Energy Co Ltd (SPI)-エネルギー分野：企業M&A・提携分析
    Summary SPI Energy Co Ltd (SPI Energy), formerly Solar Power Inc, is a renewable energy company that offers photovoltaic solutions. The company operates in development, financing, installation, operation and sale of utility-scale and residential solar power projects in China. It also operates online …
  • Steris Plc (STE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Steris Plc (Steris), formerly Steris Ltd is a medical equipment company that provides infection prevention and other procedural products. The company offers products such as OR integration systems, sterilizers, surgical tables and lights, perioperative solutions, endoscopy accessories and ba …
  • Natera Inc (NTRA)：企業の財務・戦略的SWOT分析
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers Panorama, a non-invasive prenatal screening test that analyzes baby's DNA through a simple blood dra …
  • Trevena Inc (TRVN)：企業の財務・戦略的SWOT分析
    Summary Trevena Inc (Trevena) is a biotechnology company that discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination w …
  • Adient Plc (ADNT)：企業の財務・戦略的SWOT分析
    Adient Plc (ADNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bunge Ltd (BG)：企業の財務・戦略的SWOT分析
    Bunge Ltd (BG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Emerson Electric Co (EMR)：電力：M&Aディール及び事業提携情報
    Summary Emerson Electric Co. (Emerson) is a provider of infrastructure technologies and life cycle services for information and communication technology systems. The company offers hardware and software solutions for power, thermal and infrastructure management under the brands of Kop-Flex, jaure, a …
  • Mobile Tornado Group Plc (MBT)：企業の財務・戦略的SWOT分析
    Summary Mobile Tornado Group Plc (Mobile Tornado) is a technology company that offers communication services. The company offers solutions such as instant messaging solutions, voice communication, one-to-one and one-to-many; and instant alert that enables workforce to raise alerts in a range of situ …
  • Highmark Inc：企業の戦略的SWOT分析
    Highmark Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Lee’s Pharmaceutical Holdings Ltd (950)：製薬・医療：M&Aディール及び事業提携情報
    Summary Lee's Pharmaceutical Holdings Ltd (Lee's Pharmaceutical) is a biopharmaceutical company that offers development of novel therapies and contract research services. The company provides products in the treatment of disease areas such as urology, cardiovascular oncology, dermatology, hematology …
  • Reins International Inc.：企業の戦略・SWOT・財務分析
    Reins International Inc. - Strategy, SWOT and Corporate Finance Report Summary Reins International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • European Investment Bank：企業の戦略的SWOT分析
    European Investment Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Worldpay Group Ltd：企業の戦略・SWOT・財務分析
    Worldpay Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Worldpay Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Oglethorpe Power Corporation
    Oglethorpe Power Corporation - Strategy, SWOT and Corporate Finance Report Summary Oglethorpe Power Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Graftys SA：製品パイプライン分析
    Summary Graftys SA (Graftys) is a medical device company that focuses on the development, manufacture and commercialization of synthetic bioactive orthopedic biomaterials. It provides a wide range of synthetic and bioresorbable bone graft substitutes and other cement products. The company’s products …
  • Nidek Co Ltd：企業の戦略的SWOT分析
    Nidek Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • QuantuMDx Group Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary QuantuMDx Group Ltd (QuantuMDx) is a developer of sciences tools and diagnostics products. The company’s products include Q-POC, a handheld DNA analyzer that provides an accurate molecular diagnostic results. It develops assays for diagnosis and drug susceptibility testing of infectious dise …
  • EndoCeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary EndoCeutics Inc (EndoCeutics) is a pharmaceutical company that develops hormone sensitive cancer prevention therapies for women’s health. The company's pipeline products include drugs for various indications such as endometriosis, male hypogonadism and antiandrogens, among others. It develop …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆